23.04.2018 Fresenius SE & Co. KGaA  DE0005785604

DGAP-Adhoc: Fresenius SE & Co. KGaA: Akorn, Inc. sues Fresenius for consummation of merger agreement after its termination by Fresenius


 
DGAP-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Mergers & Acquisitions/Legal Matter Fresenius SE & Co. KGaA: Akorn, Inc. sues Fresenius for consummation of merger agreement after its termination by Fresenius 23-Apr-2018 / 16:53 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Akorn, Inc. sues Fresenius for consummation of merger agreement after its termination by Fresenius Akorn, Inc. filed a lawsuit today against Fresenius at the Court of Chancery in Delaware, USA, for the consummation of the merger agreement. Akorn, Inc. argues that Fresenius was obliged to close the transaction because all closing conditions of the merger agreement, except FTC clearance, were met. Fresenius believes that the lawsuit is without foundation, because Akorn failed to fulfill several closing conditions. Among others, Fresenius' independent investigation found material breaches of FDA1 data integrity requirements relating to Akorn's operations. Fresenius will take all necessary and appropriate measures to vigorously contest the claims. Fresenius does not intend to provide further updates as the lawsuit proceeds. 1 FDA: Food and Drug Administration Fresenius SE & Co. KGaA, represented by Fresenius Management SE, The Management Board Bad Homburg v.d.H., April 23, 2018 ---------------------------------------- Contact: Markus Georgi Senior Vice President Investor Relations T: +49 (0) 6172 608-2485 [email protected] ---------------------------------------- End of note --------------------------------------------------------------------------- 23-Apr-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: [email protected] Internet: www.fresenius.com ISIN: DE0005785604, DE000A2DANS3 WKN: 578560 , A2DANS Indices: DAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxemburg End of Announcement DGAP News Service --------------------------------------------------------------------------- 677783 23-Apr-2018 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 33.530,00 35.409,00 37.250,00 36.277,00 37.520,00 40.840,00 22.299,00
EBITDA1,2 6.267,00 6.032,00 7.083,00 7.132,00 6.854,00 6.808,00 3.422,00
EBITDA-Marge3 18,69 17,04 19,01 19,66 18,27 16,67
EBIT1,4 4.589,00 5.251,00 4.631,00 4.385,00 4.158,00 3.321,00 1.143,00
EBIT-Marge5 13,69 14,83 12,43 12,09 11,08 8,13 5,13
Jahresüberschuss1 1.816,00 1.871,00 1.915,00 2.823,00 2.819,00 2.117,00 -594,00
Netto-Marge6 5,42 5,28 5,14 7,78 7,51 5,18 -2,66
Cashflow1,7 3.937,00 3.742,00 4.263,00 6.549,00 5.078,00 4.198,00 4.456,00
Ergebnis je Aktie8 3,25 3,37 3,44 3,06 3,26 2,44 -1,05
Dividende8 0,75 0,80 0,84 0,88 0,92 0,92 0,62
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578560 26,900 Halten 15.151,08
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
12,93 16,59 0,77 10,83
KBV KCV KUV EV/EBITDA
0,80 3,40 0,68 8,30
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,92 0,00 0,00 17.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 31.07.2024 06.11.2024 20.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
4,93% -0,94% -4,17% 6,58%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius SE & Co. KGaA  ISIN: DE0005785604 können Sie bei EQS abrufen


Medtech , 578560 , FRE , XETR:FRE